Document is current
Any future updates will be listed below
-
Authors
Cvachovec, Paula
Bicu, Alicia S.
Schmidt, Ralf
Siefert, Victor
Eckl, Miriam
Willam, Marvin
Clausen, Sven
Froelich, Matthias F.
Schoenberg, Stefan O.
Ehmann, Michael
Buergy, Daniel
Fleckenstein, Jens
Giordano, Frank A.
Boda-Heggemann, Judit
Dreher, Constantin
-
Funding
Funding for this research was provided by:
Medizinische Fakultät Mannheim der Universität Heidelberg
- License Information
-
More Information
Article History
Received: 29 December 2024
Accepted: 23 April 2025
First Online: 7 May 2025
Declarations
:
: DB reports NB Capital ApS (Consultation, personal fees), PharmaMar GmbH (speaker), AstraZeneca GmbH (speaker). FG reports travel expenses, stocks and honoraria from TME Pharma AG related to this work; research grants and travel expenses from ELEKTA AB; grants, research grants, travel expenses and honoraria from Carl Zeiss Meditec AG; grants, research grants, travel expenses and honoraria from OncoMANGETx, Inc.; travel expenses and research grants from Varian Medical Systems, Inc.; travel expenses and/or honoraria from Bristol- Myers Squibb, Cureteq AG, Roche Pharma AG, MSD Sharp and Dohme GmbH, Siemens Healthineers AG, Varian Medical Systems, and AstraZeneca GmbH; non-financial support from Oncare GmbH and Opasca GmbH and patent US10857388B2 together with Carl Zeiss Meditec AG and patent EP4119191A1. JBH reports AstraZeneca speaker fees and consulting honoraria EbaMed SA. CD reports Varian research grant and travel expenses, AstraZeneca speaker fees and travel expenses, and DGVS speaker fees and travel expenses. All other authors have no competing interests to declare.
